Product Reports Resources Pricing Login Book a demo

Revolution Medicines

Biotech & Life Sciences · Redwood City, United States · Founded 2015 · IPO 2020

Targeted therapies for previously undruggable RAS-addicted cancers

Valuation $38B
Revenue $103M
Power Law Decacorn$10B+ valuation tier

Investors

8 investors on Revolution Medicines's cap table

Sourced from Dealroom's funding history. Investor profile links are shown where available.

Series B+ 8 investors entered at this stage
Casdin Capital
Nextech Invest
Schroder Adveq
Third Rock Ventures
Boxer Capital
Vivo Capital
The Column Group
University of Illinois Urbana Champaign

Global footprint

Where Revolution Medicines has talent and traffic

Workforce by country
🇺🇸 United States · Redwood City HQ
Book a demo for the full country breakdown
Web traffic by country
160K monthly visits
across markets
🇺🇸 United States49.6%
🇬🇧 United Kingdom6.5%
🇮🇳 India5.6%
🇨🇦 Canada5.1%
🇨🇭 Switzerland2.9%
Top 5 markets shown

Talent graph

The shape of Revolution Medicines's talent

Dealroom maps Revolution Medicines's team person by person — pinpointing the standout operators and scoring them across the six dimensions investors underwrite. The counts and shape below are a public preview; the named individuals and exact scores live in the platform.

DimensionScore
AI Talent Score hidden — book a demo
Engineering Score hidden — book a demo
Product Score hidden — book a demo
Go-to-market Score hidden — book a demo
Leadership Score hidden — book a demo
Research Score hidden — book a demo
Book a demo to unlock Revolution Medicines's exact scores

Source: Dealroom Talent Intelligence. Public profiles show counts and the team's shape only — request a demo for the named individuals, per-person seniority and tenure, and team benchmarks vs peers.

Patent intelligence

$68M patent portfolio · 86 active families

Estimated portfolio value
$68M
0.18% of market cap · 2.8× smaller than top peer Moderna Therapeutics ($189M)
86 active patent families
Where Revolution Medicines innovates BiochemistryCancer researchCarcinosisCompound sDisease

Where Revolution Medicines concentrates vs peers

Each axis is a top-10 topic across Revolution Medicines and its closest peers. #1 = 100, #10 = 10, absent = 0.

Compare against

Source: Dealroom Patent Intelligence · Patsnap. Request a demo for the full per-sub-category breakdown, individual records, and quality-score history.

Capital deployed

Revolution Medicines's 2 investments and acquisitions.

Every disclosed deal where Revolution Medicines appeared as a backer or acquirer, 2018–2023. Toggle between venture rounds, M&A, or both. The map below is grouped by the target company's sector — the colored pill on each chip is the round type.

Portfolio analysis

2 deals across Revolution Medicines's capital deployment.

Where the deals concentrate by sector, stage, and decade.

By sectorCount
    By stageCount
      By periodCount

        02 · Portfolio market map

        Revolution Medicines's portfolio, mapped.

        Each chip is one company. Pill colour shows round type — green for Seed, blue for Series A, purple for B/C+, pink for late-stage, amber for M&A. Bigger sectors keep their full list behind “+ N more”.

        Stage
        Period
        2 of 2 deals

        Market sentiment

        What the market is saying about Revolution Medicines

        An AI-synthesized read of the highest-engagement posts about Revolution Medicines on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

        Reading the room on X — pulling top posts and synthesizing themes…

        Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

        See Revolution Medicines on the full Dealroom platform

        Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.

        Book a demo Explore company profiles